Fluorinated cyclic hexapeptide somatostatin analogs, process for their preparation, intermediate products for their preparation and pharmaceutical compositions containing them
申请人:Merck & Co., Inc.
公开号:EP0104348A2
公开(公告)日:1984-04-04
Fluorinated somatostatin analogs are prepared wherein a cyclic hexapeptide contains a secondary amino acid which replaces seven of the ring amino acids of somatostatin and the Lys side chain is monofluorinated in the γ or 8 positions. The cyclic hexapeptides are easier to synthesize, have a longer duration of activity, and many have a greater level of activity than somatostatin. The compounds have the properties of inhibiting the release of glucagon, growth hormone and insulin. Certain of the compounds also are capable of inhibiting the release of gastric acid secretions. The compounds are particularly useful in the treatment of acromegaly, diabetes, diabetic retinopathy and peptic ulcers. These cyclic hexapeptides are prepared by the solid phase method.
氟化索马司他汀类似物的制备过程中,环状六肽含有一个仲氨基酸,取代了索马司他汀的七个环状氨基酸,赖氨酸侧链在γ或8位被单氟化。环六肽更容易合成,活性持续时间更长,而且许多环六肽的活性高于索马司他汀。这些化合物具有抑制胰高血糖素、生长激素和胰岛素释放的特性。某些化合物还能抑制胃酸分泌的释放。这些化合物尤其适用于治疗肢端肥大症、糖尿病、糖尿病视网膜病变和消化性溃疡。这些环六肽是通过固相法制备的。